about
Nucleus accumbens deep-brain stimulation efficacy in ACTH-pretreated rats: alterations in mitochondrial function relate to antidepressant-like effectsStress, Inflammation, and Cellular Vulnerability during Early Stages of Affective Disorders: Biomarker Strategies and Opportunities for Prevention and Intervention.Progesterone: The neglected hormone in schizophrenia? A focus on progesterone-dopamine interactions.Cell Death Pathways: a Novel Therapeutic Approach for Neuroscientists.Why should neuroscientists worry about iron? The emerging role of ferroptosis in the pathophysiology of neuroprogressive diseases.Current and Emerging Pharmacotherapies for Cessation of Tobacco Smoking.Peripheral proinflammatory markers associated with ketamine response in a preclinical model of antidepressant-resistance.Chronic adrenocorticotrophic hormone treatment alters tricyclic antidepressant efficacy and prefrontal monoamine tissue levels.Leaky brain in neurological and psychiatric disorders: Drivers and consequencesIncidence and characteristics of the nocebo response from meta-analyses of the placebo arms of clinical trials of olanzapine for bipolar disorderStatins and Inflammation: New Therapeutic Opportunities in PsychiatryProtocol and Rationale: A 24-week Double-blind, Randomized, Placebo Controlled Trial of the Efficacy of Adjunctive Linn. (Mangosteen) Pericarp for SchizophreniaInsulin-stimulated mTOR activation in peripheral blood mononuclear cells associated with early treatment response to lithium augmentation in rodent model of antidepressant-resistanceThe Therapeutic Potential of Mangosteen Pericarp as an Adjunctive Therapy for Bipolar Disorder and SchizophreniaMyalgic encephalomyelitis/chronic fatigue syndrome: From pathophysiological insights to novel therapeutic opportunitiesShared pathways for neuroprogression and somatoprogression in neuropsychiatric disordersNeurobiology and Therapeutic Potential of Cyclooxygenase-2 (COX-2) Inhibitors for Inflammation in Neuropsychiatric DisordersHas the sun set for seasonal affective disorder and HPA axis studies? A systematic review and future prospectsBiomarker-Guided Anti-inflammatory Therapies: From Promise to Reality CheckThe compensatory antioxidant response system with a focus on neuroprogressive disorders
P50
Q27336543-4F7F73F8-9BB7-49C2-902B-15AA53838627Q37705451-F2673355-4BE8-4F4A-B2A9-41F8FAF69813Q38823229-637B50E7-4781-4F51-88F5-722E3EC4D715Q46279808-3945EFDB-DB8E-4F65-B4EA-010D5C64A581Q47242531-8D183AE1-CBB2-4CA8-A644-86458DE540B7Q47563458-9CDF3EB8-1AC2-4E24-8D39-54B32AF136A0Q47629326-EA83A7C9-46AE-49B5-BA7D-38C0001BC32DQ47928632-90D8E7B6-5CE1-41FA-BF6A-1A2DBB6ED560Q59209445-4B291D84-9CFA-43F4-B1D2-95A07A69C729Q59209486-3438A56E-98CA-46EB-91EC-E2FE40E40754Q64062792-02DA5EF8-F4AD-4B28-B594-FBD5E0FD5855Q64078141-1F62E984-C3EE-4CF4-823D-A586E1CC3098Q64091418-A9E7C20B-BA21-44AE-81C6-C763608B6457Q64098164-C1B9A737-B717-4E52-A8A1-454AF0B737F0Q90061074-F4759F2E-E683-4BF1-919D-9C2E0041D747Q90220091-0B1A4D8E-CBBA-407B-867E-37302C3E52B5Q90264439-4DA97018-B0B5-4AD5-8B15-390239E6639AQ91831653-48CC5499-6AD3-4413-9C6E-5CD4146734A4Q91850098-0FCF2989-9F54-4B13-8F98-B8D6AEF5B15CQ92219778-57DF1720-F2E0-497B-930A-7F8CB2FD59FA
P50
description
researcher, ORCID id # 0000-0002-5399-1245
@en
wetenschapper
@nl
name
Adam Walker
@ast
Adam Walker
@en
Adam Walker
@es
Adam Walker
@nl
type
label
Adam Walker
@ast
Adam Walker
@en
Adam Walker
@es
Adam Walker
@nl
prefLabel
Adam Walker
@ast
Adam Walker
@en
Adam Walker
@es
Adam Walker
@nl
P106
P1153
55557224400
P1960
3jeu9CYAAAAJ
P21
P31
P496
0000-0002-5399-1245